BRCA1 functions as a classical tumor suppressor in breast and ovarian cancer. While the role of BRCA1 in homology-directed repair of DNA double-strand breaks contributes to its tumor suppressive ...
FAIRFAX, VA--(Marketwired - March 07, 2016) - In light of conflicting and inconclusive clinical data on the benefit of radiation therapy in cancer patients with the BRCA1 and BRCA2 mutation, a ...
Treatment based On BRCA1 level does not increase survival of stage II/III NSCLC N+ resected patients
Yokohama, Japan - Oct. 17, 2017 - New research shows that treating stage II and III non-small cell lung cancer (NSCLC) N+ resected patients with customized chemotherapy (CT) treatment based on their ...
Two new studied have investigated the mechanisms underlying the treatment resistance associated with some BRCA1 mutations, and the findings provide information that may help predict which treatments ...
Deborah Kelly and Zhi Sheng, assistant professors at the Virginia Tech Carilion Research Institute, recently received a grant from the Commonwealth Health Research Board to investigate hereditary ...
A new research has revealed that BRCA1, the breast cancer susceptibility gene, plays an important role in non-small cell lung cancer (NSCLC). Hence, it can also be used to predict outcome for patients ...
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia
Our analysis included 133 AML patients (60 females and 73 males, median age 62 years, range 16–85 years), diagnosed between April 1995 and October 2004. The diagnosis of AML was established according ...
COX-2 status is a significant factor to predict a postoperative survival as well as an efficacy of postoperative adjuvant therapy in non-small cell lung cancer No significant financial relationships ...
Background Women with a breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2) mutation are at increased risk for developing breast and ovarian cancer. Various ...
RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...
Deborah Kelly and Zhi Sheng, assistant professors at the Virginia Tech Carilion Research Institute, recently received a grant from the Commonwealth Health Research Board to investigate hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback